Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07700264

A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents

This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. NEMO-I delivers evidence-based psychological techniques-such as mindfulness, self-regulation training, and emotion monitoring-in a gamified format consisting of seven brief activities that users can complete at home in about 10 minutes each.

A total of 140 middle and high school students will participate. Participants will complete standardized neuropsychological and psychological assessments before and after the intervention period. During the 21-day intervention period, participants will use the NEMO-I application at home each day at their convenience (a minimum of 10 minutes per day is recommended). By comparing pre- and post-intervention assessment results, this study seeks to determine whether the application produces meaningful benefits for adolescent mental health and to establish its suitability as a digital mental health tool.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

12 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seoul Women's University

Seoul, 01797, South Korea

Location contact

Hyunjoo Song, PhD

PRINCIPAL_INVESTIGATOR

Myeongjie Im, MA

CONTACT

[email protected]

+82-10-2588-0859

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Middle or high school students currently enrolled in school
  • Using an Android-based smartphone
  • Voluntary agreement to participate, with consent from a legal guardian

Exclusion criteria

  • Borderline intellectual functioning or intellectual disability (IQ below 80)
  • Visual or hearing impairment
  • Prior diagnosis of intellectual, visual, or hearing impairment

Treatment and study plan

NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)

Behavioral

NEMO-I is a mobile application that delivers evidence-based psychological techniques in a gamified format. It consists of seven brief activities-including facial expression imitation, singing, breathing and stretching with nature sounds, reading tips for everyday concerns, rhythm-based instrument play, room decoration, and mindfulness-each designed to be completed at home in about 10 minutes. Participants use the application daily during the 21-day intervention period, at their convenience, with a recommended minimum of 10 minutes per day.

Primary outcomes

  1. Change in depressive symptoms

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. Change is assessed by comparing pre- and post-intervention scores.

  2. Change in inhibitory control (Color-Word Stroop Test, CWST)

    Time frame: Baseline(pre-intervention) and after the 21-day intervention period

    Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process. Performance is indexed by response time and error rate under the color-word interference condition. Change is assessed by comparing pre- and post-intervention performance.

  3. Change in anxiety symptoms

    Time frame: Baseline(pre-intervention) and after the 21-day intervention period

    Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms. Higher scores indicate greater anxiety. Change is assessed by comparing pre- and post-intervention scores.

  4. Change in neuro-cognitive and emotional function (NEMO-A)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks. It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function. Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance.

  5. Change in visual attention and processing speed (Children's Color Trails Test, CCTT)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT). Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.

  6. Change in set-shifting ability (Trail Making Test-B, TMT-B)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence. Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.

Secondary outcomes

  1. Change in subjective stress

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Subjective stress is measured using a Visual Analog Scale (VAS), on which participants rate their current perceived stress level from 1 (no stress) to 10 (extreme stress).

  2. Change in daily stress

    Time frame: Baseline(pre-intervention) and after the 21-day intervention period

    Daily stress is measured using a 26-item self-report scale assessing stress experienced in everyday domains such as parents, school, academics, peer relationships, appearance, and finances, rated on a 5-point Likert scale.

  3. Change in alexithymia

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Difficulty identifying and describing one's own emotions is measured using the Korean version of the 20-item Toronto Alexithymia Scale (TAS-20K), rated on a 5-point Likert scale.

  4. Change in executive function difficulties (self-report)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Self-reported executive function difficulties are measured using the Brief Self-Report Questionnaire of Executive Function Difficulty for children and adolescents (40 items), rated on a 3-point Likert scale.

  5. Change in peer relationship quality

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    The quality of peer relationships is measured using a 13-item self-report scale rated on a 4-point Likert scale, including items reflecting conflict and negative peer interactions.

  6. Change in problem behaviors (CBCL 6-18, parent report)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Problem behaviors are assessed using the Child Behavior Checklist for Ages 6-18 (CBCL 6-18), completed by a parent or primary caregiver. It includes internalizing problems (e.g., anxiety, depression, somatic complaints) and externalizing problems (e.g., rule-breaking, aggressive behavior).

  7. Change in ADHD symptoms (ARS, parent report)

    Time frame: Baseline (pre-intervention) and after the 21-day intervention period

    Attention-deficit/hyperactivity symptoms are assessed using the ADHD Rating Scale (ARS), an 18-item parent-report questionnaire comprising inattention and hyperactivity/impulsivity subscales.

Study contacts

Contact information is provided by the study sponsor or research team.

Myeongjie Im, MA

CONTACT

[email protected]

+82-10-2588-0859

Sponsors and collaborators

Lead sponsor

Seoul Women's University

Other

Collaborators

  • Korea Health Industry Development Institute
  • Ministry of Health & Welfare, Korea

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 14, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.